Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $609,000.

  • Keros Therapeutics' Amortizatization of Intangibles rose 8.17% to $609,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 49.08%. This contributed to the annual value of $1.8 million for FY2024, which is 17.27% up from last year.
  • Per Keros Therapeutics' latest filing, its Amortizatization of Intangibles stood at $609,000 for Q3 2025, which was up 2.35% from $595,000 recorded in Q2 2025.
  • Keros Therapeutics' Amortizatization of Intangibles' 5-year high stood at $609,000 during Q3 2025, with a 5-year trough of $99,000 in Q1 2021.
  • Over the past 3 years, Keros Therapeutics' median Amortizatization of Intangibles value was $522,000 (recorded in 2023), while the average stood at $469,091.
  • In the last 5 years, Keros Therapeutics' Amortizatization of Intangibles surged by 157.14% in 2023 and then plummeted by 35.06% in 2024.
  • Keros Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $198,000 in 2021, then soared by 62.12% to $321,000 in 2022, then grew by 4.36% to $335,000 in 2023, then soared by 70.75% to $572,000 in 2024, then grew by 8.17% to $609,000 in 2025.
  • Its last three reported values are $609,000 in Q3 2025, $595,000 for Q2 2025, and $584,000 during Q1 2025.